Compare Berkshire Hathaway Inc Class B (BRK.B) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Berkshire Hathaway Inc Class B vs Johnson & Johnson — how do they compare? Berkshire Hathaway Inc Class B trades at $487.7, while Johnson & Johnson trades at $254.41 (market cap $611.07B). The key difference: Johnson & Johnson pays a 2.11% dividend while Berkshire Hathaway Inc Class B pays none, and Johnson & Johnson is trading nearer its 52-week high, Berkshire Hathaway Inc Class B nearer its low. Which is the better fit depends on your goals.
| BRK.B | JNJ | |
|---|---|---|
Sector | Financials | Health |
52-Week High | $513.70 | $267.24 |
52-Week Low | $459.10 | $155.17 |
Market Cap | — | $611.07B |
Volume | — | 6,156,228 |
Enterprise Value | — | $644.01B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BRK.B trades at $488.5, down 1.67% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. Support levels are near $483-$489, while resistance sits at $495-$501. Analyst consensus is positive with 57% buy ratings, though key financial ratios are not provided in the current data.
The outlook remains cautiously optimistic due to strong analyst support and technical bullish signals, but risks include market volatility and reliance on broader economic conditions. Investors should monitor upcoming earnings for fundamental clarity amid missing valuation metrics.
Johnson & Johnson (JNJ) trades at $257.77, up 0.31% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $94.19B, net income margin of 21.83%, and consistent earnings beats. Recent dividend declaration of $1.34 and positive analyst coverage with 52.5% buy ratings reinforce confidence. The current price sits near pivot point resistance at $258, with technical indicators showing bullish momentum from moving averages.
JNJ presents a compelling long-term investment with stable cash flows, strong profitability metrics, and defensive healthcare positioning. Upside potential exists toward the $281 consensus price target, though risks include rising debt-to-asset ratio (24.06% in 2025) and patent expiration headwinds. The stock's 60+ year dividend growth history provides income stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
